Dr. Marc Hedrick's presentation at the BioCentury Future Leaders in the Biotech Industry presentation on April 15, 2011

1. Cytori Therapeutics, Inc. NASDAQ: CYTX BioCentury Future Leaders Marc H. Hedrick, MD, President April 15, 2011

2. Safe Harbor Statement This presentation may contain certain ‘forward-looking statements’. All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. The forward-looking statements included in this presentation are also subject to a number of material risks and uncertainties. We caution investors not to place undue reliance on the forward-looking statements contained in this presentation. We would advise reading our annual report filed with the United States Securities and Exchange Commission on Form 10-K for a more detailed description of these risks.

4. Cardiovascular Pipeline

5. Customers Developing New “Apps”

6. Cosmetic & Reconstruction Commercialization

7. Barriers to Entry

10. Multipotent cells

11. Endothelial cells

12. Vasc. smooth muscle cells

13. Tissue resident macrophages

16. Available for ADVANCE trial

20. Cardiovascular Pipeline

21. Customers Developing New “Apps”

22. Cosmetic & Reconstruction Commercialization

23. Barriers to Entry

29. Leverage 30+ ADVANCE trial sites

31. Initial: self pay, open coding, new technology payments

32. Future: Precise + registry = DRG

34. LVEF difference of 5.7% (SPECT)

35. 3.5x improvement perfusion

37. Three arms: 20 MM cells, 30 MM cells, & placebo

38. Up to 35 centers

40. Cardiovascular Pipeline

41. Customers Developing New “Apps”

42. Cosmetic & Reconstruction Commercialization

43. Barriers to Entry

45. SUI

46. Liver

47. Renal

48. Malignant wounds

49. Cardiomyopathy

50. Vocal cord paralysis

51. HIV therapy-induced soft tissue atrophy

52. Others Common theme: Acute or chronic ischemic tissue

54. Moderate to severe Incontinence

55. Single treatment

56. All improved10 weeks Post-Celution Treatment Nagoya & Nagasaki, Japan

58. Cardiovascular Pipeline

59. Customers Developing New “Apps”

60. Cosmetic & Reconstruction Commercialization

61. Barriers to Entry

64. 75% pt satisfaction on (12-mo)

65. Improvement in scar, pigmentation, symmetry and defect index (6-Mo):

66. 2.8 to 3.9 in ptassessment (0-5 scale)

67. 3.1 to 4.1 in phys. assessment (0-5 scale)Binary patient and physician satisfaction with treatment results at 6- and 12-months 19

68. EU Market Analysis for Restore Procedure Ex. 1- Based on EU Hospital Penetration Ex. 2- Based on UK Patient Adoption 2,000 Procedures/Year Number of Hospitals Note- Backlog: 2 mm patients 1 System in 10% of hospitals using 1 consumable/day = $146 MM UK only- 10% penetration of incidence = $25 MM/year

71. Minimally invasive , out-patient

73. NICE evaluation

74. France, Germany, Italy, Spain, Switzerland, and UK

75. Pursue reimbursement on regional basis

76. Marketed under name RESTORE Procedure

77. Support patient awareness/education (www.cellreconstruct.eu)

80. Multiple in Europe

81. Minimal training requirements units shipped in 2010 since Q2 launch (1,000 + in Q4)

82. Commercial Performance: Systems and Consumables Consumable Growth Growing Installed Base

83. Commercial Performance: Revenue

85. Cardiovascular Pipeline

86. Customers Developing New “Apps”

87. Cosmetic & Reconstruction Commercialization

88. Barriers to Entry

92. Branding

93. Create customer loyalty with quality product and service

94. Protect, use and enforce trademarks

95. Marketing support 27

97. Cardiovascular Pipeline

98. Customers Developing New “Apps”

99. Cosmetic & Reconstruction Commercialization

100. Barriers to Entry

104. Thank You